The levels of Il-17A, which is a pro-inflammatory cytokine engaged in the pathogenesis of various autoimmune disorders [27], were increased at 8 h after ConA administration, and GRMS-55 decreased the concentrations of this cytokine at both dose levels. Here, IL17A is linked to autoimmune disease.